Who
Thomas O. Daniel
Director
Company insider
Files Form 4 as: Director, Gossamer Bio; Director, Dianthus Therapeutics; Director, Larimar Therapeutics; Director, Juno Therapeutics; Officer, Celgene Corp /de/.
In numbers
- Trades disclosed
- 160
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $31.3M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 1 Mar 2012
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 6 Jun 2024filed 6 Jun 2024 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 28 Jun 2022filed 30 Jun 2022 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 9 Jun 2022filed 15 Jul 2022 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2021filed 10 Jun 2021 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 1 Jun 2021filed 3 Jun 2021 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,188 at $0.00 | filing |
| 12 May 2021filed 17 May 2021 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 29 Sep 2020filed 30 Sep 2020 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,600 at $0.00 | filing |
| 17 Jun 2020filed 18 Jun 2020 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 5 Jun 2020filed 9 Jun 2020 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,188 at $0.00 | filing |
| 26 Jun 2019filed 27 Jun 2019 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 10 Jun 2019filed 11 Jun 2019 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —23,500 at $0.00 | filing |
| 7 Jun 2019filed 11 Jun 2019 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,188 at $0.00 | filing |
| 12 Feb 2019filed 12 Feb 2019 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code C | —171,429 | filing |
| 12 Feb 2019filed 12 Feb 2019 | GOSS Gossamer BioBiotechnology | SEC FORM 4 Code C | —38,095 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.